Dual inhibition of cathepsin G and chymase is effective in animal models of pulmonary inflammation

Bruce E. Maryanoff, Lawrence De Garavilla, Michael N. Greco, Barbara J. Haertlein, Grace I. Wells, Patricia Andrade-Gordon, William M. Abraham

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Rationale: Mast cells and neutrophils are key contributors to the pathophysiological inflammatory processes that underpin asthma and chronic obstructive pulmonary disease, partly through the release of noxious serine proteases, including cathepsin G (Cat G) andchymase.Fromthis standpoint, a dual inhibitor of neutrophil Cat G and mast cell chymase could protect against these disease-related inflammatory responses. Objectives: We examined the antiinflammatory pharmacology of RWJ-355871, a dual inhibitor of CatGand chymase, in animal models of inflammation that evince pathophysiological pathways relevant to asthma and chronic obstructive pulmonary disease to determine the therapeutic potential of this compound. Methods: In an ovalbumin (OVA)-sensitized rat model, RWJ-355871 was administered to block the mast-cell-mediated increase in paw volume caused by OVA injection. In a sheep asthma model, antigeninduced airway responses were assessed with and without aerosol treatment with RWJ-355871. In a murine tobacco-smoke model of airway inflammation, the effect of RWJ-355871 on smoke-induced neutrophilia was determined. Measurements and Main Results: Intravenous treatment of OVAsensitized rats with RWJ-355871 provided dose-dependent reduction in the increase in rat paw volume. In allergic sheep, aerosol pretreatment with RWJ-355871 showed dose-dependent inhibition of the antigen-induced early response, late response, and post-antigen-induced airway hyperreponsiveness. In tobacco-smoke-exposed mice, nebulized RWJ-355871 significantly reduced the smoke-induced neutrophilia from the levels observed in untreated mice. Conclusions: The preclinical antiinflammatory effects of RWJ-355871 in these animal models of inflammation indicate that this dual inhibitor may have therapeutic utility for treating airway inflammatory diseases involving mechanisms that depend on Cat G and/or chymase.

Original languageEnglish
Pages (from-to)247-253
Number of pages7
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume181
Issue number3
DOIs
StatePublished - Feb 1 2010
Externally publishedYes

Fingerprint

Cathepsin G
Chymases
Pneumonia
Animal Models
Smoke
Mast Cells
Asthma
Ovalbumin
Inflammation
Aerosols
Chronic Obstructive Pulmonary Disease
Tobacco
Sheep
Neutrophils
Anti-Inflammatory Agents
Antigens
Gastrin-Secreting Cells
JNJ-10311795
Serine Proteases
Therapeutics

Keywords

  • Asthma
  • Enzyme inhibitor
  • Mast cells
  • Neutrophils
  • Pulmonary disease
  • Serine protease
  • Tobacco smoke

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

Maryanoff, B. E., De Garavilla, L., Greco, M. N., Haertlein, B. J., Wells, G. I., Andrade-Gordon, P., & Abraham, W. M. (2010). Dual inhibition of cathepsin G and chymase is effective in animal models of pulmonary inflammation. American Journal of Respiratory and Critical Care Medicine, 181(3), 247-253. https://doi.org/10.1164/rccm.200904-0627OC

Dual inhibition of cathepsin G and chymase is effective in animal models of pulmonary inflammation. / Maryanoff, Bruce E.; De Garavilla, Lawrence; Greco, Michael N.; Haertlein, Barbara J.; Wells, Grace I.; Andrade-Gordon, Patricia; Abraham, William M.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 181, No. 3, 01.02.2010, p. 247-253.

Research output: Contribution to journalArticle

Maryanoff, BE, De Garavilla, L, Greco, MN, Haertlein, BJ, Wells, GI, Andrade-Gordon, P & Abraham, WM 2010, 'Dual inhibition of cathepsin G and chymase is effective in animal models of pulmonary inflammation', American Journal of Respiratory and Critical Care Medicine, vol. 181, no. 3, pp. 247-253. https://doi.org/10.1164/rccm.200904-0627OC
Maryanoff, Bruce E. ; De Garavilla, Lawrence ; Greco, Michael N. ; Haertlein, Barbara J. ; Wells, Grace I. ; Andrade-Gordon, Patricia ; Abraham, William M. / Dual inhibition of cathepsin G and chymase is effective in animal models of pulmonary inflammation. In: American Journal of Respiratory and Critical Care Medicine. 2010 ; Vol. 181, No. 3. pp. 247-253.
@article{38119cafcd1641e58fcb89cc1be239e0,
title = "Dual inhibition of cathepsin G and chymase is effective in animal models of pulmonary inflammation",
abstract = "Rationale: Mast cells and neutrophils are key contributors to the pathophysiological inflammatory processes that underpin asthma and chronic obstructive pulmonary disease, partly through the release of noxious serine proteases, including cathepsin G (Cat G) andchymase.Fromthis standpoint, a dual inhibitor of neutrophil Cat G and mast cell chymase could protect against these disease-related inflammatory responses. Objectives: We examined the antiinflammatory pharmacology of RWJ-355871, a dual inhibitor of CatGand chymase, in animal models of inflammation that evince pathophysiological pathways relevant to asthma and chronic obstructive pulmonary disease to determine the therapeutic potential of this compound. Methods: In an ovalbumin (OVA)-sensitized rat model, RWJ-355871 was administered to block the mast-cell-mediated increase in paw volume caused by OVA injection. In a sheep asthma model, antigeninduced airway responses were assessed with and without aerosol treatment with RWJ-355871. In a murine tobacco-smoke model of airway inflammation, the effect of RWJ-355871 on smoke-induced neutrophilia was determined. Measurements and Main Results: Intravenous treatment of OVAsensitized rats with RWJ-355871 provided dose-dependent reduction in the increase in rat paw volume. In allergic sheep, aerosol pretreatment with RWJ-355871 showed dose-dependent inhibition of the antigen-induced early response, late response, and post-antigen-induced airway hyperreponsiveness. In tobacco-smoke-exposed mice, nebulized RWJ-355871 significantly reduced the smoke-induced neutrophilia from the levels observed in untreated mice. Conclusions: The preclinical antiinflammatory effects of RWJ-355871 in these animal models of inflammation indicate that this dual inhibitor may have therapeutic utility for treating airway inflammatory diseases involving mechanisms that depend on Cat G and/or chymase.",
keywords = "Asthma, Enzyme inhibitor, Mast cells, Neutrophils, Pulmonary disease, Serine protease, Tobacco smoke",
author = "Maryanoff, {Bruce E.} and {De Garavilla}, Lawrence and Greco, {Michael N.} and Haertlein, {Barbara J.} and Wells, {Grace I.} and Patricia Andrade-Gordon and Abraham, {William M.}",
year = "2010",
month = "2",
day = "1",
doi = "10.1164/rccm.200904-0627OC",
language = "English",
volume = "181",
pages = "247--253",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "3",

}

TY - JOUR

T1 - Dual inhibition of cathepsin G and chymase is effective in animal models of pulmonary inflammation

AU - Maryanoff, Bruce E.

AU - De Garavilla, Lawrence

AU - Greco, Michael N.

AU - Haertlein, Barbara J.

AU - Wells, Grace I.

AU - Andrade-Gordon, Patricia

AU - Abraham, William M.

PY - 2010/2/1

Y1 - 2010/2/1

N2 - Rationale: Mast cells and neutrophils are key contributors to the pathophysiological inflammatory processes that underpin asthma and chronic obstructive pulmonary disease, partly through the release of noxious serine proteases, including cathepsin G (Cat G) andchymase.Fromthis standpoint, a dual inhibitor of neutrophil Cat G and mast cell chymase could protect against these disease-related inflammatory responses. Objectives: We examined the antiinflammatory pharmacology of RWJ-355871, a dual inhibitor of CatGand chymase, in animal models of inflammation that evince pathophysiological pathways relevant to asthma and chronic obstructive pulmonary disease to determine the therapeutic potential of this compound. Methods: In an ovalbumin (OVA)-sensitized rat model, RWJ-355871 was administered to block the mast-cell-mediated increase in paw volume caused by OVA injection. In a sheep asthma model, antigeninduced airway responses were assessed with and without aerosol treatment with RWJ-355871. In a murine tobacco-smoke model of airway inflammation, the effect of RWJ-355871 on smoke-induced neutrophilia was determined. Measurements and Main Results: Intravenous treatment of OVAsensitized rats with RWJ-355871 provided dose-dependent reduction in the increase in rat paw volume. In allergic sheep, aerosol pretreatment with RWJ-355871 showed dose-dependent inhibition of the antigen-induced early response, late response, and post-antigen-induced airway hyperreponsiveness. In tobacco-smoke-exposed mice, nebulized RWJ-355871 significantly reduced the smoke-induced neutrophilia from the levels observed in untreated mice. Conclusions: The preclinical antiinflammatory effects of RWJ-355871 in these animal models of inflammation indicate that this dual inhibitor may have therapeutic utility for treating airway inflammatory diseases involving mechanisms that depend on Cat G and/or chymase.

AB - Rationale: Mast cells and neutrophils are key contributors to the pathophysiological inflammatory processes that underpin asthma and chronic obstructive pulmonary disease, partly through the release of noxious serine proteases, including cathepsin G (Cat G) andchymase.Fromthis standpoint, a dual inhibitor of neutrophil Cat G and mast cell chymase could protect against these disease-related inflammatory responses. Objectives: We examined the antiinflammatory pharmacology of RWJ-355871, a dual inhibitor of CatGand chymase, in animal models of inflammation that evince pathophysiological pathways relevant to asthma and chronic obstructive pulmonary disease to determine the therapeutic potential of this compound. Methods: In an ovalbumin (OVA)-sensitized rat model, RWJ-355871 was administered to block the mast-cell-mediated increase in paw volume caused by OVA injection. In a sheep asthma model, antigeninduced airway responses were assessed with and without aerosol treatment with RWJ-355871. In a murine tobacco-smoke model of airway inflammation, the effect of RWJ-355871 on smoke-induced neutrophilia was determined. Measurements and Main Results: Intravenous treatment of OVAsensitized rats with RWJ-355871 provided dose-dependent reduction in the increase in rat paw volume. In allergic sheep, aerosol pretreatment with RWJ-355871 showed dose-dependent inhibition of the antigen-induced early response, late response, and post-antigen-induced airway hyperreponsiveness. In tobacco-smoke-exposed mice, nebulized RWJ-355871 significantly reduced the smoke-induced neutrophilia from the levels observed in untreated mice. Conclusions: The preclinical antiinflammatory effects of RWJ-355871 in these animal models of inflammation indicate that this dual inhibitor may have therapeutic utility for treating airway inflammatory diseases involving mechanisms that depend on Cat G and/or chymase.

KW - Asthma

KW - Enzyme inhibitor

KW - Mast cells

KW - Neutrophils

KW - Pulmonary disease

KW - Serine protease

KW - Tobacco smoke

UR - http://www.scopus.com/inward/record.url?scp=76749104410&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76749104410&partnerID=8YFLogxK

U2 - 10.1164/rccm.200904-0627OC

DO - 10.1164/rccm.200904-0627OC

M3 - Article

C2 - 19875688

AN - SCOPUS:76749104410

VL - 181

SP - 247

EP - 253

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 3

ER -